posted on 2016-04-11, 00:00authored byX Zhang, W Zhang, SF Ma, AA Desai, S Saraf, G Miasniakova, A Sergueeva, Tatiana Ammosova, M Xu, S Nekhai, T Abbasi, NG Casanova, MH Steinberg, CT Baldwin, P Sebastiani, JT Prchal, R Kittles, JG Garcia, RF Machado, VR Gordeuk
Background. We postulated that the hypoxic response in sickle cell disease (SCD) contributes to altered gene expression and pulmonary hypertension, a complication associated with early mortality.
Methods and Results. To identify genes regulated by the hypoxic response and not other effects of chronic anemia, we compared expression variation in peripheral blood mononuclear cells from 13 SCD subjects with hemoglobin SS genotype and 15 Chuvash polycythemia subjects (VHLR200W homozygotes with constitutive up-regulation of hypoxia inducible factors in the absence of anemia or hypoxia). At 5% false discovery rate, 1040 genes exhibited >1.15 fold change in both conditions; 297 were up-regulated and 743 down-regulated including MAPK8 encoding a mitogen-activated protein kinase important for apoptosis, T-cell differentiation and inflammatory responses. Association mapping with a focus on local regulatory polymorphisms in 61 SCD patients identified expression quantitative trait loci (eQTL) for 103 of these hypoxia response genes. In a University of Illinois SCD cohort the A allele of a MAPK8 eQTL, rs10857560, was associated with pre-capillary pulmonary hypertension defined as mean pulmonary artery pressure 25 and pulmonary capillary wedge pressure 15 mm Hg at right heart catheterization (allele frequency=0.66; OR=13.8, P=0.00036, n=238). This association was confirmed in an independent Walk-PHaSST cohort (allele frequency=0.65; OR=11.3, P=0.0025, n=519). The homozygous AA genotype of rs10857560 was associated with decreased MAPK8 expression and present in all 14 identified pre-capillary pulmonary hypertension cases among the combined 757 patients.
Conclusions. Our study demonstrates a prominent hypoxic transcription component in SCD and a MAPK8 eQTL associated with pre-capillary pulmonary hypertension.
Funding
This work was supported in part by grants R01 HL111656
and K23HL098454 (to R.F.M.); R01 HL079912-04 and 2
R25-HL03679-08 (to V.R.G.); HL RC2 101212 and R01 HL 87681
(to M.H.S., C.T.B., and P.S.); MO1-PR10284, SC1GM082325,
2G12RR003048, and 8G12MD007597 (to S.N.); 1P30HL107253 (to
V.R.G. and S.N.); and NIH-P01CA108671 and VAH (to J.T.P.).
History
Publisher Statement
Post print version of article may differ from published version. The definitive version is available through American Health Association at DOI:10.1161/CIRCULATIONAHA.113.005296